Core Viewpoint - The "Healthy China 2030" plan emphasizes achieving national health and longevity as a key indicator of national prosperity and revitalization, with a focus on high-quality development in the domestic pharmaceutical industry [1] Group 1: Company Overview - Qilu Pharmaceutical, representing the industry, adheres to the philosophy of "integrating creation and imitation," with a planned R&D investment exceeding 4.3 billion yuan in 2024 and a cumulative investment of over 20 billion yuan during the 14th Five-Year Plan period [3] - The company has established R&D centers in multiple locations, including Seattle, San Francisco, Boston, Shanghai, Hainan, and Jinan, employing over 5,200 dedicated R&D personnel [3] Group 2: Product and Market Impact - Qilu Pharmaceutical's product Medaxin® was included in the national drug centralized procurement list in December 2019, benefiting over 100 million cardiovascular disease patients in China and significantly reducing their economic burden [1] - As of November this year, Qilu has 109 products that have won bids or renewed contracts, with 30 centralized procurement drugs exported to 33 countries and regions [1] Group 3: Research and Development Achievements - The company is currently developing over 80 innovative drugs and is efficiently advancing 20 of them through clinical trials [3] - Qilu Pharmaceutical leads the industry in several metrics, including nearly 300 brand-name generic drugs in development, and has the highest number of consistency evaluations and national centralized procurement wins [5] - The company has launched 16 biosimilars and holds 530 invention patents, with 42 major new drug creation projects under the national science and technology major special program since the 12th Five-Year Plan [5] Group 4: Global Strategy - Qilu Pharmaceutical implements a "global consistency, co-line production" strategy and has been conducting simultaneous submissions for drug approvals in China and international regulatory bodies since 2013 [5] - It is the only domestic pharmaceutical company exporting formulations to the EU, the US, the UK, Japan, Australia, and Canada, with 38 products holding the top market share in their respective overseas markets, serving approximately 1.5 billion people globally each year [5]

Core Insights - The Chinese pharmaceutical industry is currently the second largest in the world, having significantly improved its competitiveness over the past decade, transitioning from "catching up" to "keeping pace" and even "leading" in certain areas [1] - Qilu Pharmaceutical, as a representative of national pharmaceutical companies, is committed to high-quality development and has made substantial contributions to the industry [1] Group 1: National Drug Procurement Participation - By November 2025, Qilu Pharmaceutical has 109 products that have been awarded bids or renewed, with 30 of these drugs also being exported to 33 countries and regions, benefiting both domestic and global patients [2] - The drug Medaxin, included in the national drug procurement list, has successfully replaced original research drugs, demonstrating excellent performance in real-world studies, with data from nearly 360,000 patients confirming its efficacy and safety [2] - Medaxin has benefited over 100 million cardiovascular disease patients in China, significantly reducing their economic burden of medication and exemplifying the active participation of national pharmaceutical companies in drug procurement [2] Group 2: Global Reach and Quality Assurance - Qilu Pharmaceutical's products benefit approximately 1.5 billion people globally each year, adhering to the principle of "global uniformity and shared production lines," ensuring high standards for both domestic and international markets [3] - Since 2013, Qilu Pharmaceutical has implemented a "dual reporting" system for drug approvals, submitting the same products for registration with both the Chinese National Medical Products Administration and international regulatory bodies [3] - The company has established multiple collaborations with international organizations, including the United Nations Development Programme, to enhance global public health accessibility and has expanded its market presence in emerging regions such as the Middle East, North Africa, Central Asia, Southeast Asia, and Latin America [3]